United Therapeutics Corporation (UTHR) Stock Overview
Explore United Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.
United Therapeutics Corporation (UTHR)
Key Financials
Key Financials
Market Cap
22.6B
P/E Ratio
17.94
EPS (TTM)
$27.09
ROE
0.19%
UTHR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of United Therapeutics Corporation (UTHR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 36.98, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $513.54.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.94 and a market capitalization of 22.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.